Language:

Does Statin Benefits Patients with Heart Failure Undergoing Percutaneous Coronary Intervention? Findings from the Melbourne Interventional Group Registry

Cardiovascular drugs and therapy, 2018-02, Vol.32 (1), p.57-64 [Peer Reviewed Journal]

Springer Science+Business Media, LLC, part of Springer Nature 2018 ;Cardiovascular Drugs and Therapy is a copyright of Springer, (2018). All Rights Reserved. ;ISSN: 0920-3206 ;EISSN: 1573-7241 ;DOI: 10.1007/s10557-018-6769-y ;PMID: 29349644

Full text available

Citations Cited by

Actions
1. Add to My Research
2. Remove from My Research
3. E-mail
4. Print
5. Permalink
6. Citation
7. EasyBib
8. EndNote
9. RefWorks
10. Delicious
11. Export RIS
12. Export BibTeX

Title:
Does Statin Benefits Patients with Heart Failure Undergoing Percutaneous Coronary Intervention? Findings from the Melbourne Interventional Group Registry
Author: Chin, Ken Lee ; Wolfe, Rory ; Reid, Christopher M. ; Tonkin, Andrew ; Hopper, Ingrid ; Brennan, Angela ; Andrianopoulos, Nick ; Duffy, Stephen J. ; Clark, David ; Ajani, Andrew ; Liew, Danny
Subjects: Aged ; Angioplasty ; Cardiology ; Cardiovascular diseases ; Clinical outcomes ; Clinical trials ; Confidence intervals ; Coronary Artery Disease - diagnosis ; Coronary Artery Disease - mortality ; Coronary Artery Disease - physiopathology ; Coronary Artery Disease - therapy ; Female ; Health risk assessment ; Heart ; Heart diseases ; Heart failure ; Heart Failure - diagnosis ; Heart Failure - mortality ; Heart Failure - physiopathology ; Heart Failure - therapy ; Humans ; Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects ; Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use ; Intervention ; Male ; Medicine ; Medicine & Public Health ; Mortality ; Myocardial infarction ; Myocardial Infarction - etiology ; Original Article ; Patient Readmission ; Patients ; Percutaneous Coronary Intervention - adverse effects ; Percutaneous Coronary Intervention - mortality ; Registries ; Risk analysis ; Risk Factors ; Statins ; Statistical analysis ; Time Factors ; Treatment Outcome ; Victoria
Is Part Of: Cardiovascular drugs and therapy, 2018-02, Vol.32 (1), p.57-64
Description: Purpose The effectiveness of statins in improving clinical outcomes among patients with heart failure (HF) undergoing percutaneous coronary intervention (PCI) is unclear. We examined the association between use of statins and clinical outcomes in patients with HF included in the Melbourne Interventional Group registry. Methods Patients were followed from 30 days to 1 year post-PCI for a primary composite outcome of all-cause mortality and hospitalisation for cardiovascular (CV) causes. Secondary outcomes included major adverse cardiac events (MACE, a composite of all-cause mortality, myocardial infarction and target vessel revascularisation) and hospitalisation for CV causes. Outcomes were compared between statin-treated and non-statin-treated patients (at 30 days post-PCI) using propensity scores to balance for risk factors. Results Among 991 patients included in the inverse probability-weighted Cox model, statin use had no significant effect on the primary composite outcome [adjusted hazard ratio (aHR), 1.03; 95% confidence interval (CI), 0.68 to 1.56; p = 0.89], nor MACE (aHR, 0.99; 95% CI, 0.54 to 1.84; p = 0.99) or hospitalisation for CV causes (HR, 1.13; 95% CI, 0.74 to 1.72; p = 0.57). Conclusions Our results suggest that statin therapy may confer no significant benefits in patients with HF undergoing PCI. However, prospective randomised controlled trials are needed to provide more definitive answers.
Publisher: New York: Springer US
Language: English
Identifier: ISSN: 0920-3206
EISSN: 1573-7241
DOI: 10.1007/s10557-018-6769-y
PMID: 29349644
Source: MEDLINE
ProQuest Central

Back to results list


INSPIRE LIBRARY - TON DUC THANG UNIVERSITY	(84-028) 37 755 057	Feedback
19 Nguyen Huu Tho St. Dist.7, HCM	thuvien@tdtu.edu.vn	Feedback

Does Statin Benefits Patients with Heart Failure Undergoing Percutaneous Coronary Intervention? Findings from the Melbourne Interventional Group Registry

Springer Science+Business Media, LLC, part of Springer Nature 2018 ;Cardiovascular Drugs and Therapy is a copyright of Springer, (2018). All Rights Reserved. ;ISSN: 0920-3206 ;EISSN: 1573-7241 ;DOI: 10.1007/s10557-018-6769-y ;PMID: 29349644

Searching Remote Databases, Please Wait